Epigenetic inhibition of hedgehog pathway signalling in tumours
Nature Medicine
2014년6월30일
A method to overcome one type of drug resistance in some instances of brain or skin cancer in mice, by using an epigenetic inhibitor of the hedgehog signalling pathway, is reported online in Nature Medicine. This offers a new avenue for therapy where present drugs targeting the hedgehog signalling pathway, which drives tumour growth and development, have been hindered by emerging drug resistance.
The hedgehog signalling pathway leads to activation of the Gli proteins which in turn contribute to the signalling cascade that promotes tumour growth and development. To block hedgehog signalling, Yoon-Jae Cho and colleagues targeted the BET protein family of chromatin regulators-molecular complexes that regulate gene expression.
They found that inhibiting BET proteins with a small molecule, JQ1, could decrease expression of Gli proteins. JQ1 impaired the growth of tumours in mice that were sensitive or resistant to hedgehog pathway inhibitor drugs, suggesting that targeting epigenetic regulators of gene expression, such as the BET proteins, downstream in the pathway could be an effective adjunctive treatment for these tumours.
doi: 10.1038/nm.3613
리서치 하이라이트
-
2월18일
Nature Energy Focus issue: How extreme weather events disrupt energy systemsNature Energy
-
1월28일
Materials science: Increased nuclear waste storage corrosion at material interfacesNature Materials
-
1월9일
Ecology: Reassessing impacts of ocean acidification on fish behaviourNature
-
12월20일
Marine biology: Acidified oceans may corrode shark scalesScientific Reports
-
12월19일
Anthropology: The final stand of Homo erectusNature
-
12월17일
Energy: Health and financial impacts of time-of-use energy rates raise equity concernsNature Energy
